MGNX
MacroGenics, Inc.
MGNX lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
MGNX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Under pressure | |
| Unavailable |
MGNX's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
MGNX PE Valuation
MGNX has no meaningful PE right now: it lost money over the past year.
MGNX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect MGNX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
MGNX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.82 | +$0.37 |
| Q2 2026 | -$0.23 | +$0.33 |
| Q1 2026 | -$1.11 | -$0.23 |
| Q4 2025 | -$1.18 | -$0.11 |
| Q3 2025 | -$1.19 | +$0.38 |
| Q2 2025 | -$0.56 | +$1.63 |
| Q1 2025 | -$0.88 | -$0.50 |
| Q4 2024 | -$1.07 | -$0.92 |
MGNX is still losing money, but far less than before: $0.82 per share over the past year, against $3.56 at its worst in mid-2022.
MGNX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.7M | -74% |
| Q2 2026 | $32.8M | +48% |
| Q1 2026 | $20.8M | +57% |
| Q4 2025 | $41.2M | +113% |
| Q3 2025 | $72.8M | -34% |
| Q2 2025 | $22.2M | +106% |
| Q1 2025 | $13.2M | +45% |
| Q4 2024 | $19.4M | +81% |
MGNX's revenue has slid since its 2024 peak: $19M last quarter, down 74% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -109% | -134 points |
| Q2 2026 | -42% | +123 points |
| Q1 2026 | -161% | +162 points |
| Q4 2025 | -29% | +244 points |
| Q3 2025 | 26% | -23 points |
| Q2 2025 | -165% | +374 points |
| Q1 2025 | -323% | +267 points |
| Q4 2024 | -273% | +187 points |
MGNX's operating margin was −109% last quarter, down 134 points from the same quarter a year ago.
MGNX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.4M | +$24.2M |
| Q2 2026 | -$41.6M | +$6.1M |
| Q1 2026 | -$36.2M | +$11.3M |
| Q4 2025 | $42.8M | +$81.8M |
| Q3 2025 | -$30.6M | -151% |
| Q2 2025 | -$47.7M | -$2.2M |
| Q1 2025 | -$47.4M | -$317K |
| Q4 2024 | -$39M | -$10.4M |
MGNX has burned cash in almost every quarter: −$41M over the past year, against −$165M the year before.
MGNX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +149K shares |
| 1 year | +0.7% | +460K shares |
| 3 years | +2.4% | +1.5M shares |
| 5 years | +4.2% | +2.6M shares |
| Available history | +33% | +15.7M shares |
MGNX has 64M diluted shares, up 0.7% from a year ago.
MGNX Net Leverage
MGNX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MGNX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.1 | Neutral |
| Stochastic | 16.0 | Oversold |
MGNX's weekly RSI is 35 (neutral) and its Stochastic is 16 (oversold).
MGNX PE vs Healthcare Sector
| Metric | MGNX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MGNX has no meaningful PE right now: it lost money over the past year.
MGNX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.95 | 22% below |
| 20 week MA | $3.68 | 38% below |
| 50 week MA | $3.11 | 26% below |
| 100 week MA | $2.51 | 8.8% below |
| 200 week MA | $4.78 | 52% below |
MGNX is in a downtrend: it's below all five of its weekly moving averages, and 52% below its 200-week average.
MGNX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.8 | $24.3 | +126% |
| 2021 | $24.3 | $17.4 | -28% |
| 2022 | $17.4 | $5.94 | -66% |
| 2023 | $5.94 | $9.62 | +62% |
| 2024 | $9.62 | $3.23 | -66% |
| 2025 | $3.23 | $1.61 | -50% |
| 2026 YTD | $1.61 | $2.29 | +42% |
MGNX's yearly returns have swung widely, from +126% in 2020 to −66% in 2024. It's up 42% so far in 2026.